GOSS Stock — Gossamer Bio Inc.: Cash, EV, Pipeline

What they do

Our goal is to be an industry leader in, and to enhance the lives of patients living with, PH. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world.

Source: 10-K FY2025 via SEC EDGAR

Share price

$9.77

Market cap

$59.8M

Cash

$57.0M

Enterprise value

$2.8M

Balance sheet

Cash	$57.0M
Debt	$0.0M
Net cash	$57.0M
Enterprise value	$2.8M
Basic shares	488.8M shares
Fully diluted shares	1,098.5M shares
Fully diluted market cap	$10,732.2M
Cash per share	$0.12
Quarterly burn	$39.4M
Cash runway	1.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

488.8M

Pre-funded warrants

33.4M

Options

54.7M

RSUs

6.6M

Warrants

166.5M

Converts

348.5M

Conv preferred

0.0M

ESPP reserve

—

FDSO

1,098.5M

Cap table as of 2026-06-30.

Price history

Loading GOSS daily closes…

Loading price history…

Next catalyst

seralutinib · Est. Nov 7, 2026 · guidance midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now guidance midpoint	seralutinib NDA filing acceptance decision (PAH)	Not disclosed	acceptance (PAH)	late 2026
Jan 12 - Feb 23 in 9 wks	Seralutinib	Phase 3	Pulmonary Arterial Hypertension	—
Jan 12 - Feb 23 in 14 mo	GB002 (seralutinib)	Phase 2	Pulmonary Arterial Hypertension	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

seralutinib

Phase 3 · Active Modality: inhaled small molecule

Aliases GB002

Target PDGFR / CSF1R / c-KIT

Partnerships Pulmokine (in-license; up to $48M development/regulatory milestones, now a XOMA Royalty subsidiary); Chiesi (collaboration terminated July 23, 2026; Gossamer reacquired worldwide rights under Rights Reacquisition Agreement)

Indications

pulmonary arterial hypertension (Stage not disclosed)

Status note Phase 3 PROSERA trial in PAH did not meet its primary endpoint at the prespecified significance threshold. Open-label extension studies remain active.

RT234

Stage not disclosed · Active

Target PDE5

Partnerships Respira Therapeutics (option agreement)

Indications

pulmonary arterial hypertension (Stage not disclosed)
pulmonary hypertension associated with interstitial lung disease (Stage not disclosed)

Catalysts

— None

Status note Complementary on-demand therapeutic opportunity being advanced in a capital-efficient manner under the Respira option agreement.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Seralutinib
Lead indication	Pulmonary Arterial Hypertension
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06274801	Phase 3	Recruiting	Sponsor	GOSS	—	Pulmonary Arterial Hypertension	—
NCT04816604	Phase 2	Active, not recruiting	Sponsor	GOSS	—	Pulmonary Arterial Hypertension	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Gossamer Bio USA, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	17,841,000	+17,841,000	0.52%	2026-08-14
ADAR1 Capital Management	212,531	-75,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

GOSS — Gossamer Bio Inc. ☆